Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

FEMARA® (letrozole) - Summary of Product Characteristics


Click below to download the FEMARA® Summary of Product Characteristics for the following European countries


Femara® (letrozole) Summary of Product Characteristics - Europe (PDF)

Please note: The information in this Summary of Product Characteristic is valid for the countries listed above and may contain information that is outside the approved product information in the country in which you are located. Please contact your local Novartis affiliate or visit your country site (where available) for obtaining specific product information for your country.


For more details on early and long-term benefits seen with FEMARA® in the pivotal BIG 1-98 trial, click here.

Click here for Important Safety Information for FEMARA®.